Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP DT-2502
- Development stage
- Preclinical
- Lead developer
- Daewoo Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWP DT-2502 is an investigational small molecule drug candidate being developed by Daewoo Pharma for the treatment of peptic ulcer disease. As of early 2024, the project is in the formulation stage of development, representing an early-phase asset in the company's gastrointestinal R&D pipeline. While specific details regarding its molecular target or chemical composition have not been publicly disclosed, it is part of a suite of candidates Daewoo is advancing for acid-related disorders, alongside more advanced projects like DWP DT-2402. The drug is likely intended for oral administration, consistent with standard treatments for peptic ulcers.
Beyond the preview
Go deeper on DWP DT-2502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP DT-2502.